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Fibroblastic reticular cells (FRC) form the structural backbone of the T cell rich zones
in secondary lymphoid organs (SLO), but also actively influence the adaptive immune
response. They provide a guidance path for immigrating T lymphocytes and dendritic
cells (DC) and are the main local source of the cytokines CCL19, CCL21, and IL-7, all
of which are thought to positively regulate T cell homeostasis and T cell interactions
with DC. Recently, FRC in lymph nodes (LN) were also described to negatively regulate
T cell responses in two distinct ways. During homeostasis they express and present a
range of peripheral tissue antigens, thereby participating in peripheral tolerance induction
of self-reactive CD8+ T cells. During acute inflammation T cells responding to foreign
antigens presented on DC very quickly release pro-inflammatory cytokines such as
interferon γ. These cytokines are sensed by FRC which transiently produce nitric oxide
(NO) gas dampening the proliferation of neighboring T cells in a non-cognate fashion. In
summary, we propose a model in which FRC engage in a bidirectional crosstalk with both
DC and T cells to increase the efficiency of the T cell response. However, during an acute
response, FRC limit excessive expansion and inflammatory activity of antigen-specific
T cells. This negative feedback loop may help to maintain tissue integrity and function
during rapid organ growth.
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Secondary lymphoid organs (SLO), such as lymph nodes (LN)
and spleen, are essential for efficient initiation of adaptive
immune responses. Their structure is thought to optimize anti-
gen concentration and presentation to naive recirculating lym-
phocytes and allow for rapid selection and proliferation of
antigen-specific T and B lymphocytes, as well as their dif-
ferentiation into effector cells. To make these processes more
efficient SLO are compartmentalized into functionally distinct
microenvironments: the B zone (follicle or outer cortex), T zone
(LN paracortex or splenic periarteriolar lymphoid sheath), and
entry and exit zones. Three-dimensional networks of specialized
radio-resistant fibroblasts (CD45- Ter119- CD31-) are respon-
sible for generating and maintaining these B- and T-cell rich
compartments. On the one hand, follicular dendritic cells (FDC;
CD21/35+ FDC-M1/2+) inside B zones constitutively produce
the chemokine CXCL13 to attract and retain B cells. On the other
hand, fibroblastic reticular cells (FRC; CD21/35- gp38+) inside
T zones constitutively express the chemokines CCL19 and CCL21
to attract and retain T cells and antigen-presenting dendritic cells
(DC) [reviewed in (Cyster, 2005; Junt et al., 2008; Mueller and
Germain, 2009; Turley et al., 2010)]. While our understanding
of the origin and differentiation of these fibroblast subsets is still
very limited (Cyster et al., 2000; Koning andMebius, 2011), much
progress has been made in defining novel roles of FRC in adaptive
immunity.
Lymphocytes constantly recirculate between SLO. Once inside
the SLO they continue migrating using a random walk to search
their cognate antigen. T lymphocytes use the FRC network as
physical guidance during this migration. B cells often move first
across the T zone by following the FRC network before switch-
ing to the connecting FDC network when entering the B zone
(Bajenoff et al., 2006). Finally, immigrating and tissue-resident
DC associate with the T zone FRC network as well in order
to present antigens to recirculating T cells (Lindquist et al.,
2004; Bajenoff et al., 2006). It is within this FRC-rich T zone
microenvironment where DC and T cells interact to find rare
antigen-specific T cells and where some key decisions are being
taken: Is a T cell response or rather tolerance induced? If there
is a T cell response induced, what will be the type and mag-
nitude? Where will the effector T cells be directed (reviewed in
Haring et al., 2006; Junt et al., 2008; Mora et al., 2008; Mueller and
Germain, 2009)? In this review we will discuss the recent findings
which suggest that T zone FRC are not simple scaffolding cells,
but actively influence these critical decisions. A major focus will
be on the surprising finding that FRC not only enhance but may
also suppress adaptive immunity.
FRC AS POSITIVE REGULATORS OF THE T CELL RESPONSE
T zone FRC are thought to orchestrate and enhance productive
T-DC encounters in SLO by various means (Figure 1A). First,
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FIGURE 1 | FRC-expressed molecules that positively or negatively
regulate the T cell response. (A) FRC are thought to positively regulate T cell
immunity in several ways. Throughout the T zone of SLO FRC form a
three-dimensional network that serves as a scaffold for DC adhesion and T cell
migration, thereby increasing DC-T interaction. In addition, FRC constitutively
produce CCL19 and CCL21 that retain T cells in the T zone while increasing
their motility. FRC also constitutively produce IL-7 that promotes T cell survival.
CCL19, CCL21, and IL-7 may all serve as co-stimulatory signals in case of
weak T cell receptor triggering. (B) FRC express several molecules that may
negatively regulate the immune response: COX-2 and PD-L1 are constitutively
expressed, while iNOS and IDO-1 are only expressed after induction by IFNγ.
iNOS expression in FRC is also induced by other pro-inflammatory cytokines,
such as TNFα, IL-1β and IFNα (not shown). PD-L1 expression on FRC is
increased by LCMV infection, IFNγ or TLR3 stimulation (Mueller et al., 2007;
Fletcher et al., 2010; Ng et al., 2012). While blocking iNOS and COX improves
T cell proliferation in the presence of FRC, no impact of FRC-derived PD-L1,
IDO-1, CD80/86, or IL-2 on T cell proliferation has been shown. It is unclear
whether FRC can express L-arginase, but arginase inhibitors showed no effect
in vitro (Khan et al., 2011; Lukacs-Kornek et al., 2011; Siegert et al., 2011).
(C) FRC produce several factors which may regulate adaptive immunity in a
positive or negative way. They secrete extracellular matrix (ECM) proteins
some of which can bind IL-7 and CCL21 and thereby regulate cytokine
availability and localization (Katakai et al., 2004b; Förster et al., 2008; Huang
and Luther, 2012). ECM molecules may also directly modulate T cell and DC
behavior. Microarray data suggest that FRC express constitutively IL-6, which
is both anti- and pro-inflammatory depending on the context. FRC express
MHC I and low levels of MHC II, CD80, and CD40. IFNγ or TLR3 stimulation
enhances the expression of MHC I, MHC II and CD80. In addition, LCMV
infection or inflammation evoked by LPS injection in vivo can induce MHC II
expression on FRC. LN FRC express PTA, which are presented in the context
of MHC I, leading to T cell proliferation followed possibly by clonal deletion of
self-reactive T cells. Therefore, in certain settings FRC may act as APC.
the FRC network acts as a 3D “road system” for T cells forcing
them to pass by antigen-presenting DC attached to FRC, pre-
sumably enhancing the frequency of encounters between these
two cell types (Katakai et al., 2004a; Lindquist et al., 2004; Sixt
et al., 2005; Bajenoff et al., 2006; Mueller and Germain, 2009).
This view was recently challenged by computer simulations of
T cell trafficking within the LN FRC network which showed that
mechanical guidance cues only enhance these encounters when
FRC provoke T cell streams, or when FRC also provide motility
factors such as the two CCR7 ligands CCL19 and CCL21 (Graw
and Regoes, 2012). Second, FRC are the major constitutive source
of CCL19 and CCL21, which bring T cells andDC into close prox-
imity (Luther et al., 2000; Link et al., 2007). These chemokines
also enhance the motility and survival of T cells (Stachowiak
et al., 2006; Asperti-Boursin et al., 2007; Link et al., 2007; Okada
and Cyster, 2007; Worbs et al., 2007) as well as the maturation,
dendrite formation and antigen uptake by DC (Yanagawa and
Onoé, 2002, 2003; Marsland et al., 2005). In vitro both CCL19
and CCL21 can act as co-stimulatory signals enhancing T cell
priming, especially in settings with sub-optimal T cell stimula-
tion (Flanagan et al., 2004; Friedman et al., 2006; Gollmer et al.,
2009). In vivo the importance of CCR7 for mounting efficient
T cell responses varies greatly depending on the model antigen
or pathogen used [reviewed in (Förster et al., 2008; Junt et al.,
2008)]. On the ligand side, CCL19 was shown by two laborato-
ries to be dispensable for T cell activation in vivo (Saeki et al.,
1999; Britschgi et al., 2010), with one report claiming the oppo-
site (Robbiani et al., 2000). Currently, little is known about the
in vivo role of FRC-derived CCL21, however, the lack of CCL21
expression in HEV of human LN suggests a key role for it in
lymphocyte transmigration across HEV (Carlsen et al., 2005).
Third, FRC are the major source of constitutive IL-7 expression
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in LN and thereby regulate the fitness, survival and homeosta-
sis of naive recirculating T cells (Link et al., 2007; Hara et al.,
2012; Huang and Luther, 2012). Adding or blocking IL-7 in vitro
showed little effect on T cell receptor (TCR)-dependant T cell
activation besides the improved viability of T cells andDC in pres-
ence of IL-7. However, IL-7 appears to be important in vivo for
effective interactions between DC and T cells by enhancing TCR
signaling and boosting primary antigen-specific T cell expansion
(Saini et al., 2009; Mackall et al., 2011; Pellegrini et al., 2011;
Huang and Luther, 2012). Administration of IL-7 in vivo also
augments the effector function and memory formation of T cells
(Pellegrini et al., 2011). Not surprisingly, IL-7 is regarded as an
attractive adjuvant, which is currently being investigated in sev-
eral clinical trials (Mackall et al., 2011; Huang and Luther, 2012).
In conclusion, LN FRC positively regulate T cell migration and
homeostasis. However, the evidence that FRC also augment T cell
responses, namely T cell priming as well as effector and mem-
ory differentiation, is weaker and more indirect as it is often
based on in vitro assays or on recombinant proteins expressed
non-exclusively by FRC (Figure 1A).
FRC AS NEGATIVE REGULATORS OF THE T CELL RESPONSE
Paradoxically, recent studies have proposed that FRC also neg-
atively regulate T cells, both during homeostasis and immune
responses. On one hand, FRC induce T cell tolerance via self-
antigen expression, on the other hand they can impair T cell
responses to foreign antigens by expressing suppressive factors,
either directly inhibiting T cell expansion or lowering the
immunogenicity of DC (Figures 1B,C) (Fletcher et al., 2010;
Turley et al., 2010; Khan et al., 2011; Lukacs-Kornek et al., 2011;
Siegert et al., 2011).
Similar to thymic epithelial cells (TEC), FRC from LN
were shown to constitutively express multiple peripheral tissue
restricted antigens (PTA), including known autoimmune targets
(Figures 1C, 2A) (Fletcher et al., 2010; Turley et al., 2010). They
share this feature with other LN stromal cells, such as lymphatic
and blood endothelial cells (LEC and BEC) (Cohen et al., 2010;
Fletcher et al., 2010), although the PTA are only partially overlap-
ping. However, the best characterized regulator of promiscuous
gene expression, Autoimmune regulator (Aire), was found only
in a rare EpCAM-expressing cell type in the outer T zone of LN
(Gardner et al., 2008), while Aire is poorly expressed in FRC,
LEC, and BEC (Fletcher et al., 2010) (our unpublished observa-
tion). Another potential positive regulator of promiscuous gene
expression, deformed epidermal autoregulatory factor 1 (Deaf1),
was observed to be strongly expressed in FRC as well as other
LN stromal cell types (Fletcher et al., 2010; Turley et al., 2010).
What is the functional consequence of PTA expression by FRC?
Turley and colleagues reported that in transgenic mice expressing
a truncated ovalbumin (OVA), transferred OVA-specific CD8+
T cells in peripheral LN (pLN) proliferated followed by their
partial deletion, even when MHC I was absent on hematopoi-
etic cells. Surprisingly, the intestinal fatty acid binding promoter
used to drive transgene expression led to OVA-peptide expression
FIGURE 2 | Mechanism of TRC-mediated negative regulation of T cell
expansion. (A) During homeostasis LN FRC express self-antigens (PTA),
possibly in a Deaf-1 dependent fashion. PTA presented in the context of
MHC I may lead to peripheral tolerance induction via clonal deletion of
self-reactive T cells. Cox-2 is constitutively expressed in FRC, presumably
leading to the production of PGE2 or other prostanoids that may attenuate
T cell priming or proliferation. (B) During immune response DC capture
antigen (Ag) in the periphery, home to the T zone of SLO and present
peptides of foreign antigens to recirculating T cells. Within the first 20h upon
TCR triggering, T cells produce a first wave of IFNγ and TNFα cytokines,
before entering cell cycle. In case of a very strong immune response, the
high level of pro-inflammatory cytokines induces transient iNOS expression in
the neighboring FRC and DC. The resulting NO release then acts as a
negative feedback loop slowing down T cell proliferation over the following
days presumably to ensure that the strong T cell response does not endanger
tissue integrity. High concentrations of NO may also induce T cell apoptosis.
The attenuating effect by FRC can occur in trans, without cognate interaction
with T cells. Constitutive expression of COX-2 dependent factors, such as
PGE2, may contribute to this attenuation of T cell expansion, by acting directly
or indirectly (via DC) on the proliferating T cells. Not only is there crosstalk
between FRC and T cells, but also between FRC and DC which leads to a
much stronger release of NO by these two cell types if IFNγ is present. While
the factors exchanged between FRC and DC have not yet been identified, the
may include IL-1β, IFNα, and TNFα, all of which can trigger iNOS expression.
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on MHC I selectively in gp38+ CD31− FRC of pLN along with
some expression of CD40 and CD80 (Lee et al., 2007; Fletcher
et al., 2010). Based on these findings it was proposed that FRC
can induce peripheral T cell tolerance but more direct evidence
is needed to strengthen this notion. When these transgenic mice
were bred to mice deficient in inducible nitric oxide synthase
(iNOS, NOS2), OVA-specific T cell expansion was enhanced
(Lukacs-Kornek et al., 2011). As FRC and LEC but not DC or
macrophages expressed iNOS in this system it suggests stromal
cells use nitric oxide (NO) to limit T cell expansion and pos-
sibly tolerance induction. While FRC can express MHC class
II under certain conditions, e.g., upon IFNγ stimulation (Lee
et al., 2007; Ng et al., 2012), its functional significance for tol-
erance and immunity has remained unexplored. Also unclear is
why the typically inducible cyclooxygenase-2 (COX-2) enzyme
is constitutively expressed by FRC in naive LN (Siegert et al.,
2011). COX-2 is the rate-limiting enzyme for the generation of
prostanoids, including prostaglandin E2 (PGE2), that can both
enhance or suppress T cell immunity [reviewed in (Gualde and
Harizi, 2004; Kalinski, 2012)]. It remains to be tested whether
COX-2 participates in peripheral T cell tolerance induction. In
conclusion, the existing evidence suggests that FRC and LEC
assist DC in peripheral tolerance induction of self-reactive CD8+
T cells by expressing self-antigens and NO.
Besides their tolerance-promoting role as unconventional anti-
gen presenting cells (APC), we and others recently provided
evidence for the surprising capacity of FRC to attenuate the pro-
liferation of CD4+ and CD8+ T cells in acute inflammation,
independently of antigen presentation by FRC (Khan et al., 2011;
Lukacs-Kornek et al., 2011; Siegert et al., 2011) (Figures 2A,B).
FRC did not interfere with initial TCR signaling in primed T cells
but with entry or progression in cell cycle and possibly with sur-
vival. The inhibitory effect by FRC was mainly mediated by iNOS
dependent NO production, with iNOS being strongly induced
in FRC by the synergistic action of IFNγ and TNFα. These two
cytokines are produced by CD8+ T cells less than 24 h after prim-
ing and appear to be sensed by neighboring FRC (Figure 2B)
(Khan et al., 2011; Lukacs-Kornek et al., 2011; Siegert et al.,
2011), consistent with IFNγ having been detected over a wide area
inside activated LN T zones (Beuneu et al., 2010; Perona-Wright
et al., 2010). This early burst of cytokines before blastogenesis
has previously been documented (Mempel et al., 2004; Beuneu
et al., 2010) and induces crosstalk between these two cell types,
leading to a negative feedback loop limiting T cell expansion in
case of acute inflammation. NO is a highly reactive gas which
is thought to be rapidly consumed by neighboring cells. NO
or NO-derived reactive nitrogen species may negatively regulate
T cells via nitrosylation of diverse amino acid residues, lead-
ing to down regulation of the TCR complex (Kasic et al., 2011).
Furthermore, depletion of the iNOS substrate L-arginine may
inhibit T cells, through down-regulation of CD3ζ (Rodriguez
et al., 2002). Lastly, NO may directly block STAT5 phosphory-
lation thereby interfering with IL-2 signaling (Bingisser et al.,
1998) [reviewed in Bogdan (2001), (2011)]. Notably, NO expres-
sion by FRC attenuated T cell proliferation without abrogating
it (Khan et al., 2011; Lukacs-Kornek et al., 2011; Siegert et al.,
2011). We therefore propose that FRC form micro-niches within
the T zone where T cell proliferation is either enhanced or dimin-
ished, depending on the context or phase of immune response.
Although IFNγ-stimulated FRC express other known suppres-
sive molecules, such as programmed cell death ligand 1 (PD-L1)
or Indolamin-2,3-dioxygenase (IDO) (Figure 1B), they do not
seem to be implicated in the inhibition of T cell proliferation in
the in vitro activation systems used (Khan et al., 2011; Lukacs-
Kornek et al., 2011; Siegert et al., 2011). The function of PD-L1
on FRC may be protection from CD8+ T cell-mediated cytotox-
icity, as in chronic LCMV infection (Mueller et al., 2007). A role
for IDO in FRC remains to be established. As both PD-L1 and
IDO have roles for regulatory T cells and suppressive myeloid
cells, it would be interesting to address the function of FRC in
the generation,maintenance or activation of these regulatory cells
(Francisco et al., 2010; Le Blanc and Mougiakakos, 2012).
T cell expansion was also strongly attenuated in vitro when
antigen-pulsed DC were used instead of T cell mitogens. In this
setting, both iNOS and COX-2 were responsible for the strongly
reduced T cell expansion. In comparison to proliferation, T cell
effector function (killing, IFNγ expression) was less strongly
affected (Siegert et al., 2011). Part of the attenuating effect on
T cell expansion may be due to diminished DC immunogenic-
ity. Overnight incubation of bone-marrow derived DC (BMDC)
with FRC led to a 50% reduction of CD8+ T cell stimulation
by these “FRC-conditioned” DC (Siegert et al., 2011). No dif-
ferences in the expression of MHC I or CD80/86 by DC were
observed suggesting alterations in the cytokine milieu as the
most likely cause. PGE2 may be the culprit: While it stimulates
immature DC in the periphery, it seems to be suppressive for
mature DC in SLO and decreases their APC function (Gualde
and Harizi, 2004). Interestingly, in presence of activated T cells
crosstalk between DC and FRC strongly increases iNOS expres-
sion in both cell types. Similar to a previous report on rat lung
fibroblasts (Lavnikova and Laskin, 1995), it is always only a frac-
tion of FRC and DC which express iNOS, even when FRC clones
or abundant IFNγ are used (Serbina et al., 2003; Siegert et al.,
2011). It remains to be shown whether this is due to the cell
cycle stage or a potential negative feedback loop preventing exces-
sive iNOS activity. Currently, the signals exchanged between FRC
and DC leading to iNOS expression is unclear. It seems likely
that pro-inflammatory cytokines, like IL-1β and TNFα produced
by activated DC are sensed by FRC leading to iNOS induction.
Many cytokines were recently described to be produced by FRC
(Fletcher et al., 2011; Malhotra et al., 2012), but the FRC-derived
signals stimulating iNOS expression in DC remain to be identi-
fied. In contrast to these fairly rapid attenuating effects of FRC
on DC, earlier studies have suggested that stromal cells can also
have long-term effects on DC by promoting the development of
regulatory DC which inhibit T cell responses. Adult splenic stro-
mal cells co-cultured for 1 week with splenic c-kit+ precursor
cells induced the development of CD11clow CD45RB+ regulatory
DC expressing IL-10 (Svensson et al., 2004). In another study,
neonatal splenic stromal cells converted LPS-activated BMDC
into NO-expressing regulatory DC, in a process dependent on
cell-cell contact and TGFβ (Zhang et al., 2004). In both stud-
ies, the splenic stromal cells were only partially characterized and
it is unclear whether these included FRC-like cells. These latter
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observations may be relevant for tissue development and chronic
immune responses.
That FRC exert a suppressive effect on acute T cell expansion
was best described in co-culture experiments, but in vivo experi-
ments also support this notion. When wildtype (WT) mice that
had previously received OVA-specific CD8+ T cells were infected
with OVA expressing vesicular stomatitis virus (VSV-OVA), iNOS
expression was observed only in a subset of FRC and, to a
lesser extent, DC within draining LN (Siegert et al., 2011). This
expression was detectable 24 h after infection, but not at later
time points. However, the negative effects of iNOS on T cell
expansion were clearly visible on day 4 and 8 suggesting NO
either affects T cells only during the early activation phase or
it permanently retards T cell proliferation due to longer last-
ing modifications in the target cells. Consistent with a negative
role of iNOS in vivo, VSV-OVA infected iNOS−/− mice showed
an exaggerated expansion of antigen-specific T cells compared
to WT mice (Siegert et al., 2011). When iNOS−/− mice were
immunized with OVA-loaded BMDC (Khan et al., 2011) a sim-
ilar role for NO in restraining the T cell response was found.
However, when the antigen was directly targeted to LN resident
non-inflammatory DC using OVA-coupled anti-DEC205 anti-
bodies, a decrease rather than an increase in antigen-specific T cell
expansion was observed in iNOS-deficient mice (Khan et al.,
2011). These findings support a model in which iNOS-mediated
inhibition of T cell expansion is observed only in strong TH1-
type immune responses characterized by high levels of IFNγ and
TNFα. Consistent with this notion, TH2 cytokines did not induce
iNOS in FRC and in vitro expansion of TH2 cells was not inhib-
ited by FRC or iNOS (Niedbala et al., 1999; Khan et al., 2011).
Currently it cannot be ruled out that other known iNOS sources,
such as subsets of DC and macrophages, localize to LN T zones
during TH1-type responses and contribute to these attenuating
effects (Bogdan, 2001; Serbina et al., 2003; Siegert et al., 2011).
Besides using NO within their lysosomes to kill phagocytosed
microbes, both DC and macrophages (or myeloid-derived sup-
pressor cells) can inhibit T cell proliferation in vitro by producing
extracellular NO (Albina et al., 1991; Serbina et al., 2003; Zhang
et al., 2004; Gabrilovich and Nagaraj, 2009; Siegert et al., 2011).
In an attempt to better define the effect of iNOS expression in
FRC versus DC, immune responses were investigated in irradiated
iNOS−/− mice receiving WT BM, but results were not conclusive
as these mice showed unexpected defects in LN swelling, probably
due to iNOS-dependent vascular defects induced by irradiation
(Khan et al., 2011; Siegert et al., 2011). In the future, mice with
cell type-specific deletion of iNOS are needed to firmly establish
the relative roles of the various iNOS sources in the regulation of
T cell expansion.
IFNγ stands out as a major regulator of FRC function: It
strongly induces iNOS, IDO-1, PD-L1 as well as several molecules
involved in antigen presentation (Figures 1B,C) (Mueller et al.,
2007; Fletcher et al., 2010; Khan et al., 2011; Lukacs-Kornek
et al., 2011; Siegert et al., 2011; Ng et al., 2012). Typically, IFNγ
is regarded mostly as a pro-inflammatory cytokine because it
enhances various aspects of the immune response, including the
activation of macrophages, clearance of intracellular pathogens,
up-regulation of MHC molecules or the promotion of TH1
responses. However, IFNγ also has immune-regulatory functions:
It negatively modulates expression of tissue-destructive enzymes,
diminishes the recruitment of inflammatory cells such as neu-
trophils, suppresses TH17 differentiation and positively regulates
TREG differentiation under certain circumstances [reviewed in
(Kelchtermans et al., 2008; Hu and Ivashkiv, 2009)]. Consistent
with this dual role, IFNγ can augment or suppress auto-
immunity, depending on the context and timing. A prominent
example is experimental autoimmune encephalomyelitis (EAE)
(Kelchtermans et al., 2008; Hu and Ivashkiv, 2009). In one EAE
mouse model autoimmune disease is enhanced in IFNγ-deficient
mice as indicated by the increase of proliferating T cells in the
spleen and the central nervous system (Chu et al., 2000). This
finding may be related to the observation that TH1 cells limit
their own expansion in the later phase of the immune response
by expressing IFNγ (Feuerer et al., 2006; Haring et al., 2006).
In autoimmune disease some of the protective effects mediated
by IFNγ seem to be due to its capacity to induce iNOS expres-
sion. Support for this notion comes from the observation that
self-reactivity and the associated pathology observed in exper-
imental models for EAE or myasthenia gravis are enhanced in
iNOS−/− mice (Bogdan, 2001, 2011; Shi et al., 2001; Xiao et al.,
2008). The protective effect of iNOS was also observed with
mycobacteria that are a critical part of complete Freund’s adjuvant
(CFA). When rodents are immunized with CFA they often do not
develop subsequent autoimmunity, a phenomenon termed “adju-
vant immunotherapy.” Interestingly, Kahn and colleagues showed
that this protective CFA effect depends on iNOS, as well as on
IFNγ and TNFα which are the likely inducers of iNOS within
lymphoid tissues (Kahn et al., 2001). Possibly, IFNγ-induced NO
production in FRC or other host cells participates in the active
down-regulation of T cell responses to limit tissue damage asso-
ciated with acute inflammation or autoimmunity. In the future
it will be of interest to test whether iNOS expression in myeloid
cells, FRC or other cell types is critical for this protection.
IS ATTENUATION OF T CELL PROLIFERATION A FEATURE
OF ALL MESENCHYMAL CELLS?
The suppressive activity recently observed with FRC is reminis-
cent of the increasing number of reports showing that mesenchy-
mal stem/stromal cells (MSC), as well as adult fibroblasts from
non-lymphoid tissues, potently inhibit T cell proliferation, both
in vitro and in vivo. Some reports also state that MSC reduce
the cytotoxicity and IFNγ expression in effector T cells (Haniffa
et al., 2007; Jones et al., 2007; Uccelli et al., 2008; Haniffa et al.,
2009; Khan et al., 2011; Siegert et al., 2011). Various mechanisms
of suppression have been described for MSC and non-lymphoid
fibroblasts, as summarized in Table 1 (Nauta and Fibbe, 2007;
Uccelli et al., 2008). It suggests that these suppressive pathways
are either redundant, activated in a context-dependent way or
simply due to differences in the assays used. Similar to FRC, IFNγ-
dependant induction of iNOS in MSC appears to be a major
inhibitory pathway (Nauta and Fibbe, 2007; Ren et al., 2008;
Uccelli et al., 2008), but the production of suppressive COX-1/2-
dependent prostanoids has also been reported for MSC (Nauta
and Fibbe, 2007; Ren et al., 2008; Uccelli et al., 2008). The expres-
sion of several other inhibitory molecules observed in MSC may
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Table 1 | Suppressive molecules known to be expressed in MSC versus their characterization in FRC.
Suppressive molecules
expressed by MSC
Constitutive expression References
MSC (human and murine) FRC (murine) MSC FRC
Effect on T cell activation Expressed? Effect on T cell activation
COX-2 (PGE2 ?) Attenuated T cell proliferation, Impaired Yes Attenuated CD8 T cell 4–7 1–3
maturation of monocytes into DC proliferation
HGF Attenuated T cell proliferation Yes ND 4–7 2, 3
TGFβ Attenuated T cell proliferation Yes No effect 4–7 1, 2, 3
IL-6 Impaired maturation of monocytes into DC Yes ND 4–7 2, 3
HO1 Attenuated T cell proliferation Yes ND 4–7 2, 3
Soluble HLA-G5 / Qa-2 or
H2-Q8
Attenuated T cell proliferation and cytotoxicity Yes ND 4–7 2, 3
FasL Induction of T cell apoptosis No ND 4–8 2, 3
Induced expression
Induced by Effect on T cell activation Induced by Effect on T cell activation
iNOS IFNγ Attenuated T cell proliferation IFNγ, ILß, TNFα, IFNα Attenuated T cell prolifera-
tion (CD4 and CD8)
4–7 1, 9, 10
IDO-1/2 IFNγ Attenuated T cell proliferation IFNγ No effect 4–7 1, 9
IL-10 T cell contact Release of sHLA-G5 ND No effect 4–7 1
MSC have been shown to interfere with the maturation and antigen presentation of DC and with T cell proliferation, both by cell-cell contact and various soluble
factors. Similar observations have been obtained for FRC. FRC attenuate T cell proliferation mostly by NO production, but also lower the immunogenicity of DC in
unknown ways. COX-1/2 dependent prostanoids produced by FRC may me responsible for this effect on DC. Interestingly, several candidates previously described
in MSC appear to be expressed by FRC as well, as suggested by recent gene array results. Abbreviations: HGF, Hepatocyte Growth Factor; TGFβ Transforming
Growth Factor beta; HO1, Heme Oxygenase-1; ND, not determined. References: (1) Siegert et al. (2011) (2) gene array data from Fletcher et al. (2011) (3) gene array
data from Malhotra et al., 2012 for 2 and 3: NCBI GEO accession number GSE15907, immgen.org, (4) reviewed in Uccelli et al., 2008, (5) reviewed in Haniffa et al.
(2009), (6) Sato et al. (2010) (7) reviewed in Nauta and Fibbe (2007), (8) Akiyama et al. (2012) (9) Lukacs-Kornek et al. (2011) (10) Khan et al. (2011).
be conserved in FRC and should be the focus of future studies
(Table 1). Again, reminiscent of FRC, MSC are able to present
antigens in the context of MHC II, without it being a require-
ment for their inhibitory effect (Chan et al., 2006; Stagg et al.,
2006; Uccelli et al., 2008). For antigen presentation by MSC the
IFNγ level seems to be crucial: while low levels induce MHC II
expression and APC function, both are lost with higher IFNγ con-
centrations (Chan et al., 2006). It remains to be tested whether
APC function of FRC is regulated in a similar fashion. If yes, then
this regulation would be opposite to that for iNOS expression.
Importantly, MSC have proven to successfully suppress autoim-
mune disease and graft versus host disease (Gvhd) in mice and
humans (Haniffa et al., 2007; Jones et al., 2007; Uccelli et al., 2008;
Sato et al., 2010; Le Blanc and Mougiakakos, 2012). This year
Canada approved MSC transfers as a preventive treatment for
Gvhd during bone marrow transplantations (Prochymal®, www.
osiris.com). While MSC can home both to SLO and inflamma-
tory sites it is currently not clear where and when T cell inhibition
takes place. In conclusion, most mesenchymal cell types share
with FRC T cell suppressive characteristics, independent of their
differentiation state. Interestingly, non-mesenchymal cells such
as blood and lymphatic endothelial cells from LN also suppress
T cell activation via an IFNγ/NO-dependant pathway (Khan et al.,
2011; Lukacs-Kornek et al., 2011). In addition, epithelial cells
from healthy kidney and skin or gut tumors also potently suppress
T cell expansion, indicating that this characteristic is shared with
many other cell types (Siegert et al., 2011).
WHY DO NON-HEMATOPOIETIC CELLS CONTRIBUTE
TO IMMUNE REGULATION?
The emerging concept is that hematopoietic cells are not the
sole regulators of T cell tolerance and T cell responses but that
many tissue cells can contribute, including FRC within LN. At
present we can only speculate on the reasons for this complex
regulation. One possible explanation is that the immune system
is a powerful but also dangerous weapon that needs to be tightly
controlled at many levels and anatomical sites to allow efficient
immune-mediated protection while avoiding immune-mediated
pathology. During homeostasis the body may keep most tissues
in a slightly immune-suppressed state to avoid the activation of
low affinity T cells that recognize self-antigens or harmless anti-
gens. During inflammation there may be an upper limit to the
extent of expansion allowed for a given T cell population and
a given organ. In this context, the structural cells may act as
mechanical and chemical sensors of the ongoing T cell response
in an inflamed organ and adjust population dynamics to ensure
ordered tissue growth and maintenance of functional structures.
If excessive inflammatory signals are present many tissue-specific
resident cells, including fibroblasts inside SLO or non-lymphoid
tissues, may be activated to put a brake on the immune response.
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A key function of fibroblasts is to maintain tissue integrity.
In case of damage, they have repair functions with the aim
of re-establishing homeostasis and full functionality. Both self-
reactive and beneficial, but hyperactive, T cell responses are a
serious threat for SLO and the body as a whole. Disruption of
SLO structure is frequently associated with immunodeficiency
and therefore to be avoided [reviewed in (Junt et al., 2008; Mueller
and Germain, 2009)]. So, giving structural tissue cells, like FRC,
some control over a strong ongoing T cell response appears to be a
reasonable solution to proactively protect the body. Similar to the
multiple cell types expressing self-antigens, and thereby shaping
the peripheral T cell repertoire, several cell types—hematopoietic
and non-hematopoietic—are likely to participate in the regula-
tion of responses to foreign antigens and danger signals. It will
be an important challenge to identify individual contributions,
as well as coordination, between these various regulatory cells.
Interestingly, many cell types of the immune system have a sub-
set which suppresses or regulates adaptive immunity, including
regulatory T and B cells, regulatory DC and alternatively acti-
vated M2 macrophages (Steinman et al., 2003; Lund and Randall,
2010; Murray and Wynn, 2011; Rudensky, 2011). Therefore, it
may not be surprising that LN FRC turn out to be both posi-
tive and negative regulators of adaptive immunity. Similar to the
other cell types, it remains to be established whether there is a
dedicated FRC subset for immune suppression, or whether they
are plastic and adopt an inhibitory activity, depending on the
localization (e.g., suppressive micro-niches within the T zone),
the activation status (e.g., cytokine milieu and cell-cell interac-
tions modulating FRC) and the time (e.g., phase of the immune
response). In fibroblasts and FRC some characteristics appear to
stay imprinted and they correlate with the anatomical localiza-
tion and the environment during cellular development (Chang
et al., 2002; Hammerschmidt et al., 2008; Buettner et al., 2011;
Molenaar et al., 2011). It will be a challenge for future investiga-
tions to assess in detail the complex effects FRC have on T cells,
either in the naive, activated, or memory stage. These effects are
likely to be strongly dependent on FRC density, functional spe-
cialization, environmental factors (positive and negative), and
strength and type of T cell response. Many of these studies
will rely on in vitro assays where physiological settings need to
be mimicked as closely as possible. These findings will need
confirmation from in vivo experiments. Mouse lines expressing
Cre recombinase in an FRC-specific manner are now available
(Kraman et al., 2010; Chai et al., 2011; Onder et al., 2011) and
should help to selectively manipulate molecules in FRC.
While FRC-like networks have been described for other SLO,
such as Peyer’s patches and spleen (Katakai et al., 2008; Mueller
and Germain, 2009), it remains to be established whether they are
functionally similar to LN FRC. In the placenta, mucosal surfaces,
skinandtumors, tissuefibroblastscouldalsocontributeto immune
regulation, in a way comparable to LN FRC. Tertiary lymphoid
tissues (TLT), which often develop at ectopic sites in response to
chronic inflammation, like diabetes or atherosclerosis, also con-
tain various stromal cell types found in LN, including FRC-like
cells expressing CCL19/21 and IL-7, both in mice and humans
(Manzo et al., 2005; Gräbner et al., 2009; Peduto et al., 2009; Link
et al., 2011; Perros et al., 2012). While these FRC-like cells seem
to have features positively regulating adaptive immunity within
TLT, it is currently unclear whether they also regulate it negatively.
Given the prominent IFNγ and iNOS expression in many chronic
inflammatory diseases, a contribution by fibroblastic cells appears
likely. In case of TLT developing during autoimmune disease it
would be of interest to test whether these stromal cells could
be trained to suppress self-reactive T cell responses over pro-
longed periods of time. Alternatively, depleting these ectopic FRC
or reducing their positive regulatory factors could be another
promising avenue assuming TLT are critical for pathogenesis.
As LN FRC have both positive and negative effects on immune
responses, they do not seem ideal candidates for a cellular therapy
in autoimmunity. This is in contrast to MSC and skin fibroblasts,
which are predominantly immunosuppressive. We postulate that
during evolution, when LN developed in mammals, normal tis-
sue fibroblasts were included to structure the LN (Boehm et al.,
2012). In that process they may have kept their tissue-protective,
immune-suppressive features, but have specialized further to
include functions helping lymphocytes to survive (IL-7), to local-
ize and migrate correctly (CCL19/21), to be silenced (PTA) or
to be activated (conduits, IL-7, CCL19/21). The identification of
the transcription factors, siRNA or epigenetic elements regulat-
ing the polarization of tissue fibroblasts should be an exciting
field for future studies. Most importantly, future research may
give clinicians the ability to modulate fibroblast function, either
to promote or suppress immunity, thereby leading to therapies
for treating infections, cancer and autoimmune disease.
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